Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Novavax (NVAX) shares tumble as Q2 results miss estimates, guidance cut
August 8, 2024 8:57 AM EDTNovavax (NASDAQ: NVAX) shares plunged 13.8% premarket Thursday after the vaccine maker reported second-quarter results that missed analyst expectations and lowered its full-year revenue guidance.
The company posted adjusted earnings per share of $0.99, falling short of the $1.67 consensus estimate. Revenue came in at $415 million, below the $464.83 million analysts were expecting and down slightly from... More
